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eye disease). Transition probabilities and HbA1c-dependent
adjustments came from UKPDS and other major studies. Costs
of complications came from published sources. Direct costs of
diabetes complications and SMBG were projected over patients’
lifetimes from a UK National Health Service perspective. Out-
comes were discounted at 3.5% annually. Sensitivity analysis was
performed. RESULTS: Depending on the type of diabetes treat-
ment (diet and exercise/oral medications/insulin), improvements
in glycemic control with SMBG improved discounted QALYs 
by 0.12 ± 0.14 to 0.21 ± 0.14, with increased total costs of 
£603 ± 909 to £2240 ± 1124/patient, giving incremental cost-
effectiveness ratios of £4853 to £10,670/QALY gained, well
within current UK willingness-to-pay limits. At a threshold of
£30,000/QALY gained, there was a 78–85% probability that
SMBG would be considered cost-effective. SMBG was most cost-
effective in the subgroup of patients treated with diet and exer-
cise. CONCLUSIONS: Improvements in glycemic control with
interventions including SMBG improves patient outcomes with
an acceptable cost-effectiveness ratio in the UK setting.
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OBJECTIVES: Economic evaluations of diagnostic technologies
are less well established than for therapeutic technologies. The
objective of this study was to undertake a cost-effectiveness
analysis in German ofﬁce-based centres of diagnostic strategies
with and without DaTSCAN (123I-FP-CIT) SPECT imaging for
patients with clinically uncertain Parkinsonian syndromes (PS)
to distinguish between PS and essential tremor (ET), one of the
conditions most commonly misdiagnosed as Parkinson’s Disease.
We report initial analytic results based on ofﬁce-based expert
opinion. METHODS: A Markov model was developed to simu-
late the progression of a cohort of patients with clinically uncer-
tain PS who are managed in an ofﬁce-based centre based on
clinical judgment alone or receiving DaTSCAN. Health states
were deﬁned in terms of therapy (PS, ET, none) and underlying
conditions (PS, ET). The model estimated time on potentially
beneﬁcial therapy (PBT: e.g. PS therapy for underlying PS) and
patient management costs over 5 years. Model probability inputs
were from published studies and treatment patterns/resource use
from a panel of German neurologists. Unit costs were from ofﬁ-
cial sources. The cost of a DaTSCAN test (agent plus adminis-
tration) was €929. A total of 40–60% cohort members were
assumed to have underlying PS. DaTSCAN sensitivity and speci-
ﬁcity were 95%/100% (institutional read) and 93%/97%
(blinded read). RESULTS: At 50% underlying prevalence and in
the absence of DaTSCAN, 25% of cohort members had PBT at
the outset, rising to 60% at 6 months and 62% at 5 years. Using
DaTSCAN, 99% of patients had PBT at the outset reducing to
79% at 5 years. DaTSCAN use generated an incremental 1.4 PB
years per patient, and 5-year costs were €795 lower for the
DaTSCAN group. CONCLUSION: Adding non-invasive
imaging to the management of patients with clinically uncertain
PS may be considered to be a cost-saving strategy with an
increase in time on potentially beneﬁcial therapy.
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OBJECTIVES: Cost-consequence analysis of a RP (remifentanil
+ propofol) regimen versus a conventional, commonly used MF
(midazolam + fentanyl) regimen for sedation of mechanically
ventilated postoperative cardiac surgery patients. METHODS:
We conducted a prospective, single-blinded, randomised cost-
consequence study with 80 patients in one German intensive care
unit (ICU). The RP group received remifentanil (6- max. 60mg
kg-1 h-1) and—if sedation at maximal remifentanil dose was
insufﬁcient—propofol (0.5–4.0mg kg-1 h-1). The MF group
received midazolam (0.02–0.2mgkg-1 h-1) and fentanyl (1.0–
7.0mgkg-1 h-1). Direct costs for drugs, material (variable costs
only), and staff were considered (hospital’s perspective, 2003
prices). Sensitivity and scenario analyses were performed with a
decision-analytic model. As the remifentanil dose in the study RP
regimen (baseline) was higher than in routine practice we simu-
lated a “routine practice” scenario: We lowered the mean
remifentanil infusion rate from 41.2mgkg-1 h-1 to 9mgkg-1 h-1,
increased the propofol infusion rate from 2.2mgkg-1 h-1 to 4mg
kg-1 h-1 and assumed that this scenario would have rendered the
same reduction (24%) in staff costs compared to MF regimen
and identical material and drug utilisation (except RP) as at base-
line. RESULTS: Compared to MF regimen, RP regimen (base-
line) led to a signiﬁcantly shorter mechanical ventilation time
(3.5h) and earlier discharge from ICU (18.3h) and equal average
net costs of €1700 for the ICU stay per patient. The routine prac-
tice scenario rendered 53% lower RP medication costs than base-
line thus yielding net savings of €200 per patient. These results
are sensitive to staff and drug cost variations. CONCLUSIONS:
Analysis indicates that RP regimen dominates MF regimen in the
investigated setting as it reduces the mechanical ventilation time
and hence the risk of ventilator-associated morbidity at equal
costs (baseline) or even savings (scenario).
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OBJECTIVE: To assess the usefulness of daily practice diagnos-
tic methods (medical history, I-PSS questionnaire, digital rectal
examination (DRE) and prostate-speciﬁc antigen (PSA)) for the
diagnosis of Benign Prostatic Hyperplasia (BPH). METHODS:
A total of 363 consecutive patients with suspected BPH seen at
urological outpatient clinics, between April and November 2003,
participated in the study. The following steps were sequentially
followed to deﬁne the Initial Diagnosis: 1) medical history; 2) I-
PSS questionnaire; 3) DRE; and 4) PSA. It was then compared
to the Final Diagnosis (gold-standard) after step 5) urinary sed-
iment, residual volume and prostate size by ultrasonography, and
